Beigene Ltd
HKEX:6160

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
HKEX:6160
Watchlist
Price: 106.1 HKD 1.34% Market Closed
Market Cap: 144.6B HKD
Have any thoughts about
Beigene Ltd?
Write Note

Net Margin
Beigene Ltd

-27.6%
Current
-107%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-27.6%
=
Net Income
-6.5B
/
Revenue
23.7B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CN
Beigene Ltd
HKEX:6160
146.3B HKD
-28%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
9%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country CN
Market Cap 146.3B HKD
Net Margin
-28%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 311.8B USD
Net Margin
9%
Country US
Market Cap 140.7B USD
Net Margin
13%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 102.7B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Beigene Ltd
Glance View

Market Cap
146.3B HKD
Industry
Biotechnology

BeiGene Ltd., a biopharmaceutical company with origins in Beijing, stands as a prominent player in the global fight against cancer. Founded in 2010, BeiGene has strategically positioned itself as an innovator in the field of oncology, focusing on molecularly targeted and immuno-oncology drug candidates. The company’s journey began with the vision to challenge the conventional barriers to cancer treatment, particularly in emerging markets where access to advanced therapeutics was limited. Its pipeline, robust with both internally developed and in-licensed candidates, reflects an ambitious approach to tackling various forms of cancer, including but not limited to hematological malignancies and solid tumors. The company generates revenue by developing, manufacturing, and commercializing innovative cancer therapies. BeiGene's business model is multifaceted; it involves in-house development and collaborations with international pharmaceutical giants. A significant portion of its revenue is derived from strategic partnerships, such as co-development and commercialization agreements, which allow the company to expand its market reach. Moreover, BeiGene invests heavily in research and development, which not only drives the discovery of new therapies but also strengthens its competitive edge in the pharmaceutical landscape. By balancing scientific advancement with keen market strategies, BeiGene aims to bridge the gap in global cancer care, aspiring to make life-saving treatments accessible to more patients across diverse geographies.

Intrinsic Value
177.82 HKD
Undervaluation 40%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-27.6%
=
Net Income
-6.5B
/
Revenue
23.7B
What is the Net Margin of Beigene Ltd?

Based on Beigene Ltd's most recent financial statements, the company has Net Margin of -27.6%.